Research Topics
| Marshall GlesbySummaryAffiliation: Cornell University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Osteonecrosis in patients infected with human immunodeficiency virus: a case-control studyM J Glesby
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
J Infect Dis 184:519-23. 2001..Corticosteroid use is an important risk factor for osteonecrosis, but its pathogenesis is likely multifactorial...
Oxidant stress in HIV-infected women from the Women's Interagency HIV StudyMarshall J Glesby
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Antivir Ther 14:763-9. 2009..We hypothesized that oxidant stress is associated with plasma homocysteine concentration and risk factors for atherosclerosis in HIV-infected women...- Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV StudyMarshall J Glesby
Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Antivir Ther 15:571-7. 2010..Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes... - Coronary heart disease in HIV-infected patientsMarshall J Glesby
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
Curr HIV/AIDS Rep 2:68-73. 2005..Clinicians are advised to assess coronary heart disease risk in HIV-infected patients and to intervene to reduce the impact of modifiable risk factors... - Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby
Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Pharmacol Ther 78:143-53. 2005..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir... - Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infectionMarshall J Glesby
Weill Medical College of Cornell University, New York, NY 10021, USA
J Infect Dis 191:686-93. 2005..We explored the strategy of initial immunostimulatory therapy with interleukin (IL)-2, followed by the addition of specific anti-HCV therapy, as a possible synergistic approach to treatment... - Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV StudyMarshall J Glesby
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Acquir Immune Defic Syndr 37:1604-9. 2004..Herpes zoster occurs at all CD4 cell counts in HIV-infected adults. It was hypothesized that even in the era of highly active antiretroviral therapy (HAART), zoster risk is higher in HIV-infected than uninfected women... - Bone disorders in human immunodeficiency virus infectionMarshall J Glesby
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Infect Dis 37:S91-5. 2003..An improved understanding of the pathogenesis of these bone disorders should result in better preventative and therapeutic measures... - Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected womenCarlos M Vaamonde
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
AIDS Res Hum Retroviruses 22:222-31. 2006..We conclude that higher baseline CD4 count and lower HIV RNA level were associated with poor immunologic response to HAART in women with virologic suppression for at least 6 months. Persistent low level viremia may also contribute... - Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patientsNathalie C Casau
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
J Acquir Immune Defic Syndr 32:494-8. 2003..05). Some HIV-infected patients concurrently treated with lopinavir/ritonavir and a third PI have viral suppression; many eventually discontinue therapy because of toxicity or virologic failure... - Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected menQing He
Division of Gastroenterology, Department of Medicine, St Luke s Roosevelt Hospital Center, Columbia University, New York, NY, USA
Antivir Ther 13:423-8. 2008..This study investigates the interrelationships among fat distribution, hepatic lipid content, and insulin resistance in HIV-infected men... - Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapyKristen M Marks
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
J Acquir Immune Defic Syndr 52:595-9. 2009..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV... - Switching antiretroviral therapy: why, when and howTimothy Wilkin
Weill Medical College, Cornell University, New York, USA
IAPAC Mon 12:220-9. 2006 - Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Acquir Immune Defic Syndr 37:1253-62. 2004..Overall, however, the average change in viral load across all patients was +0.03 log10 HIV RNA. Given these results, AMD3100 is not being further developed for ARV therapy, but development continues for stem cell mobilization... - Plasma homocysteine is not associated with HIV serostatus or antiretroviral therapy in womenFarbod Raiszadeh
Department of Medicine, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY, USA
J Acquir Immune Defic Syndr 51:175-8. 2009..The effects of HIV serostatus and combination antiretroviral therapy (cART) on plasma homocysteine (HCY) are uncertain... - Coronary heart disease in HIV-infected personsMarshall J Glesby
Cornell Clinical Trials Unit, Weill Medical College of Cornell University, New York, USA
AIDS Read 13:S15-9. 2003..This article focuses on coronary heart disease in persons with HIV infection... - Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infectionJeffrey M Jacobson
Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, New York 10003, USA
J Infect Dis 188:1804-14. 2003..Studies have reported that plasma human immunodeficiency virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)... - Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV studyPhyllis C Tien
Department of Medicine, University of California, San Francisco, CA 94121, USA
AIDS 23:1781-4. 2009..Further follow-up is needed to clarify whether HIV/hepatitis C virus coinfection may be associated with a greater risk of carotid plaque... - Dermatologic adverse effects of antiretroviral therapy: recognition and managementJay Luther
Upstate Medical School, State University of New York, Syracuse, New York, USA
Am J Clin Dermatol 8:221-33. 2007..Management should be individualized based on the specific drug that is implicated and the severity of the reaction... - Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
J Infect Dis 192:1943-9. 2005..The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized... - Case-control study of diabetes mellitus in HIV-infected patientsCecilia Yoon
Department of Medicine, Weill Medical College, Cornell University, New York, NY 10011, USA
J Acquir Immune Defic Syndr 37:1464-9. 2004..Diabetes mellitus (DM) is more prevalent among patients with HIV infection. Besides protease inhibitors (PIs), other factors may contribute to the development of DM... - A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087Judith A Aberg
AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
AIDS Res Hum Retroviruses 21:757-67. 2005..Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels... - Clinical manifestations associated with HTLV type I infection: a cross-sectional studyMarina F Caskey
Division of International Medicine and Infectious Diseases, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
AIDS Res Hum Retroviruses 23:365-71. 2007..9), periodontitis (OR = 10.0, 95% CI: 2.3-42.8), and dry oral mucosa (OR = 7.5, 95% CI: 1.7-32.8). HTLV-I infection is associated with a variety of clinical manifestations, which may occur in patients who have not developed myelopathy... - Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSPDaniel J Morgan
Department of International Medicine and Infectious Disease, Weill Medical College of Cornell University, New York, New York 10021, USA
AIDS Res Hum Retroviruses 23:1499-504. 2007..Conventional brain MRI frequently shows WM lesions in HTLV-I-infected individuals suggesting potential early central nervous system inflammation with rare development of progressive disease... - Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposityMichael T Yin
Division of Infectious Diseases, Columbia University Medical Center, NY, USA
Expert Rev Anti Infect Ther 3:727-38. 2005..The optimal treatment strategy, maintenance dose and duration of treatment have not been identified... - Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV StudyMichael J Silverberg
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA
Clin Infect Dis 39:717-24. 2004..The extended use of antiretroviral drugs among human immunodeficiency virus (HIV)-seropositive individuals underscores the need for a comprehensive evaluation of therapy-associated clinical symptoms... - Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicityMarshall J Glesby
AIDS Read 13:346-7. 2003 - Incidence and risk factors for verrucae in womenJacqueline C Dolev
University of California, San Francisco, California 94122, USA
AIDS 22:1213-9. 2008..To describe the incidence and risk factors for verrucae in HIV-infected and uninfected women... - Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical managementGreg T Allison
AIDS 17:1-9. 2003..Clinicians may help to prevent HIV-associated osteonecrosis by encouraging patients to limit their exposure to the established risk factors for the disease... - Low bone mineral density, HIV infection, and women: fracture or fiction?Michael T Yin
Clin Infect Dis 42:1021-3. 2006 - Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)Cecilia M Shikuma
Hawaii AIDS Clinical Research Program, John A Burns School of Medicine, University of Hawaii at Manoa, Manoa Leihi Hospital, 3675 Kilauea Avenue, Honolulu, HI 96816, USA
J Acquir Immune Defic Syndr 44:540-50. 2007..To assess metabolic changes after initiation of protease inhibitor (PI)-sparing regimens in antiretroviral-naive patients... - A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086Constance A Benson
University of California, San Diego School of Medicine, San Diego, CA 92103, USA
J Infect Dis 194:1309-18. 2006..The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain... - Total hip arthroplasty in patients with human immunodeficiency virus infection: pathologic findings and surgical outcomesCraig R Mahoney
Iowa Orthopedic Center, 411 Laurel St. #3300, Des Moines, IA 50314, USA
Acta Orthop 76:198-203. 2005..Also, the risk of infectious complications is lower in our study than previously reported in other studies of HIV-positive patients who have undergone THA... - Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infectionEllen S Engelson
Gastrointestinal Division, Obesity Research Center, New York 10025, USA
J Acquir Immune Defic Syndr 30:379-91. 2002..However, frequent adverse effects warrant controlled studies and careful patient monitoring, especially regarding glucose tolerance... - Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasisLuiz Henrique Guimaraes
School of Medicine, Oregon Health and Sciences University, Portland, OR, USA
J Infect Dis 195:142-8. 2007..Helminth infections influence the clinical outcome of and immune response to certain immune-mediated diseases... - Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical TriaBruce Shiramizu
University of Hawaii, Honolulu, Hawaii 96816, USA
J Acquir Immune Defic Syndr 33:329-35. 2003..A larger study is needed to demonstrate whether SPECT parameters alone or with other markers can provide information on fibrosis with the clinical significance obtained through liver biopsy... - Prevention strategies for cardiovascular disease in HIV-infected patientsJames H Stein
Circulation 118:e54-60. 2008 - Editorial comment: osteonecrosis in HIV-infected persons--does delayed diagnosis matter?Marshall J Glesby
AIDS Read 18:132-3. 2008 - Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US womenAudrey L French
CORE Center Stroger Cook County Hospital, Rush Medical College, Chicago, IL 60612, USA
J Infect Dis 195:1437-42. 2007..Anti-HBs levels were lower among anti-HCV-positive women. Isolated anti-HBc was rarely explained by occult HBV in this cohort but may be explained by the influence of viral coinfections on anti-HBs level or durability... - Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult Michael P Dube
Indiana University, Indianapolis, USA
Clin Infect Dis 37:613-27. 2003
Research Grants
- Growth Hormone and Rosiglitazone for Visceral AdoposityMarshall Glesby; Fiscal Year: 2007..If the results are as predicted, then combination therapy with rhGH and rosiglitazone may prove to be a highly effective treatment for visceral adiposity in HIV-infected patients. ..